Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gynecologic 2Other hematologic neoplasm 1Other 1Gastrointestinal 1Breast 1

Conditions

Motor Activity 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 71Rituximab 53Specimen Handling 47Biopsy 40Doxorubicin 39Vincristine 38Magnetic Resonance Spectroscopy 36Prednisone 35venetoclax 28obinutuzumab 26fludarabine 26Methotrexate 22ibrutinib 21Cytarabine 21Dexamethasone 20Lenalidomide 19Etoposide 18merphos 17blinatumomab 17zanubrutinib 15prednylidene 15fludarabine phosphate 15deltacortene 15acalabrutinib 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13Nivolumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Tablets × Lymphoid × 30 days × Clear all
NCT06643221 2026-06-05

Allo-X

University of Arizona

Phase EARLY_PHASE1 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Motor Activity

NCT04802590 2026-05-20

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 2 Active not recruiting
210 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡